Banyan Biomarkers Inc. is getting $7 million in funding from in vitro diagnostics specialist Biomérieux SA to help develop a blood test for traumatic brain injury (TBI). In addition, the Marcy L'etoile-France-based company has also obtained the right to commercialize Banyan's TBI tests with its Vidas immunoassays range platform.
Global Kinetics Corp. is taking a more personalized approach in monitoring Parkinson's disease symptoms. The Melbourne, Australia-based company has developed its Parkinson's Kinetigraph (PKG) system, an approved device that sits firmly in the digital health space. Recently, the private company secured a CE mark for the second generation of the PKG. The second generation system boasts technological enhancements that could ultimately allow patients to continuously monitor their condition. "PKG is a patient friendly algorithm based system," Timothy Still, president and CEO of Global Kinetics, told Medical Device Daily. "It has a smart watch that records...
Global Kinetics Corp. is taking a more personalized approach in monitoring Parkinson's disease symptoms. The Melbourne, Australia-based company has developed its Parkinson's Kinetigraph (PKG) system, an approved device that sits firmly in the digital health space.
SAN FRANCISCO – Diagnostics specialist T2 Biosystems Inc. is looking to add a new product to its sepsis detection offerings. The Lexington, Mass.-based company spoke with Medical Device Daily, during the 35th annual J.P. Morgan Healthcare Conference to discuss the product, which will detect the bacterial species associated with sepsis. T2' s president and CEO John McDonough said the company would be in a position to seek approval for the T2bacteria Panel this year. "From our standpoint the bacteria panel works the same way as our other sepsis detection panels work in measuring what happens...
SAN FRANCISCO – Diagnostics specialist T2 Biosystems Inc. is looking to add a new product to its sepsis detection offerings. The Lexington, Mass.-based company spoke with Medical Device Daily, during the 35th annual J.P. Morgan Healthcare Conference to discuss the product, which will detect the bacterial species associated with sepsis.
SAN FRANCISCO – Boston Scientific Corp. said its bid to bring its Lotus Edge transcatheter aortic valve technology (TAVR) to the U.S. will continue as planned. During a Tuesday breakout session at the 35th annual J.P. Morgan Healthcare conference, the company said the issue had been resolved. Boston Scientific also noted it wasn't a design flaw in the device nor were there any safety issues. The firm said a fix to Lotus Edge required a combination of "minor process and specification changes", rather than any meaningful, costly and lengthy product redesigns. News of the firm's...
